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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2014, TaiwanBackground: To investigate the efficacy and safety of recombinant human granulocyte colony-
stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor
(rhG-CSF) to treat sepsis in neutropenic preterm infants.
Methods: Fifty-six neutropenic preterm infants with suspected or culture-proven sepsis hospi-
talized in Zeynep Kamil Maternity and Children’s Educational and Training Hospital, Kozyatagı/
Istanbul, Turkey between January 2008 and January 2010 were enrolled. Patients were ran-
domized either to receive rhG-CSF plus empirical antibiotics (Group I) or empirical antibiotics
alone (Group II). Clinical features were recorded. Daily complete blood count was performed
until neutropenia subsided. Data were analyzed using SPSS version 11.5.
Results: Thirty-three infants received rhG-CSF plus antibiotic treatment and 23 infants
received antibiotic treatment. No drug-related adverse event was recorded. Absolute neutro-
phil count values were significantly higher on the 2nd study day and 3rd study day in Group I.
Short-term mortality did not differ between the groups.
Conclusion: Treatment with rhG-CSF resulted in a more rapid recovery of ANC in neutropenic
preterm infants. However, no reduction in short-term mortality was documented.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.il Educational and Training
Operato¨r Doktor Burhanettin
bul, Turkey.
.com (B. Demirel).
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Sepsis remains a leading cause of morbidity and mortality in
the newborn population despite modern treatment and
preventive strategies.1 Neonatal sepsis, unless it leads to ay Elsevier Taiwan LLC. All rights reserved.
172 D. Aktas‚ et almortality, prolongs duration of hospitalization, increases
the risk of long-term neurocognitive dysfunction, and con-
tributes to chronic lung disease.2e4 Bacterial sepsis is seen
in 0.1e1% of term newborns.5 It is almost 50 times more
common in extremely low birth weight infants, mostly due
to immaturity of humoral and phagocytic defense
systems.6,7
It is believed that relative immaturity of the preterm
immune system makes these babies especially prone to
lethal infections.8e10 Neutrophils play a pivotal role in de-
fense against bacterial infections.11 Neutropenia is
frequent in overwhelming sepsis and it is an ominous sign of
poor prognosis.12 Neutropenia is a persisting reduction in
neutrophil counts. It is more precisely defined as an abso-
lute neutrophil count (ANC) < 1.0  109/L.13 The unique
susceptibility of neonates to sepsis-associated neutropenia
is caused by a smaller neutrophil storage pool, a reduced
capacity for neutrophil mobilization from bone marrow
reserves, and a slower regeneration of neutrophils in the
bone marrow.14 In addition to quantitative aspects, quali-
tative features of neutrophils are also of vital impor-
tance.15 Even when peripheral neutrophil counts are
normal in premature newborns, the organisms that cause
bacterial infections are similar to those seen in older chil-
dren and adults with profound neutropenia, which is sug-
gestive of a functional neutropenia.16
Recombinant human granulocyte colony stimulating
factor (rhG-CSF) is a hematopoietic colony stimulating
factor that has been shown to specifically promote gran-
ulocyte development and maturation by stimulating
myeloid progenitor proliferation.17e19 Systematic reviews
conducted to document the efficacy and safety of rhG-CSF
administration concluded that the agent was safe, but the
evidence was insufficient to support routine use either for
treatment or for prophylaxis of neonatal sepsis.20e22
Although the level of evidence is far from adequate, he-
matopoietic growth factors have been frequently used in
neonatal intensive care units for treatment of sepsis in the
presence of neutropenia.22
We aimed to investigate the efficacy and safety of rhG-
CSF administration to treat sepsis in our neutropenic pre-
term population.2. Methods
Neutropenic preterm infants with culture-proven or sus-
pected sepsis who were hospitalized in Zeynep Kamil Ma-
ternity and Children’s Educational and Training Hospital,
Kozyatagı/Istanbul, Turkey between January 2008 and
January 2010 were enrolled in the study. Newborns with
congenital malformations, intrauterine infections, and
hydrops fetalis were regarded as ineligible for the study.
Diagnosis of sepsis was established when the following
were present within 24 hours of randomization: either fever
(axillary temperature of 38C on 1 occasion or 37.5C on
2 occasions separated by at least 1 hour) or two or more of
the following in the absence of an alternative explanation:
poor perfusion; persisting metabolic acidosis (base excess
 8mM over 4 hours in spite of corrective measures);
increasing ventilation or supplemental oxygen requirement;
 25 % reduction in platelet count from baseline or lowerlimit of normal; persisting glucose imbalance; and abdom-
inal signs (abdominal distension, blood in stool, or bilious
aspirates). Neutropenia was defined as ANC < 1.0  109/L.
When systemic signs and symptoms reminiscent of neonatal
sepsis were present, a complete blood count (CBC), C-
reactive protein, and blood smear were performed and
blood cultures (urine and cerebrospinal fluid cultures in late
sepsis) were obtained. If a microorganism was isolated from
the blood culture, the diagnosis was culture-proven sepsis.
Otherwise, diagnosis was stated as suspected sepsis.
Empirical antibiotic treatment was started as soon as the
culture specimens were obtained.
Participants of our study population were randomized
either to receive rhG-CSF plus empirical antibiotics (Group
I) or to receive empirical antibiotics alone (Group II). All
infants received supportive treatment, such as inotropes
and mechanical ventilation, when clinically indicated. rhG-
CSF (Neupogen) was administered daily at a dose of 10 mg/
kg/day in 5% dextrose (final concentration, 15 mg/mL) until
ANC reached > 1.0  109/L. At the beginning of the
research, case numbers of Groups I and II were 33 and 31,
respectively. However, eight infants in Group II received
rhG-CSF later due to intractable neutropenia (< 0.5  109/L
for  3 days) and deteriorating clinical status; therefore,
they were excluded from the study.
Blood samples were obtained via venipuncture or an
umbilical catheter. Daily CBC and blood smears were per-
formed until neutropenia subsided. ANC was calculated by
direct examination of the blood smears under light micro-
scope. When possible, 100 leukocytes were counted by the
same senior resident (D.A.) who was blinded to the study
and the ratio of neutrophils/total leukocyte count was
documented. For each infant the day at which ANC was
detected to be < 1.0  109/L was regarded as the 1st day of
the study and the day at which ANC was detected
> 1.0  109/L was accepted as the final day of the study
(recovery of neutropenia). Hemoglobin levels, white blood
cell and platelet counts, band/total and band/neutrophil
ratios, daily ANC, and duration of neutropenia were
recorded.
Clinical and demographic characteristics such as gender,
gestational age, birth weight, mode of delivery, presence
of premature rupture of membranes and preeclampsia in
the mother, presence of symptoms of sepsis in the baby,
positive blood cultures, concurrent morbidities, and mor-
tality were also recorded.
The primary outcome of our study was sepsis related
short-term mortality that occurred during hospitalization.
Secondary outcomes were correction of preexisting neu-
tropenia, rhG-CSF-related toxicity, and adverse effects
attributable to rhG-CSF therapy.
The study was approved by the local ethics committee
and written informed consent was obtained from the par-
ents. For the statistical analyses, SPSS version 11.5 (SPSS
Inc., Chicago, IL, USA) was used. To compare the differ-
ences between groups, Student t test was used when
continuous variables were distributed normally. Manne
Whitney U test was the statistical test of choice when
the distribution of continuous variables was nonhomoge-
neous. Categorical data were analyzed using c2 test or
Fischer’s exact test. A p value < 0.05 was considered
significant.
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Fifty-six neutropenic preterm infants with sepsis were
randomized. Thirty-three infants received rhG-CSF (1e4
days; median, 2 days) plus conventional medical treatment
and 23 infants received conventional medical treatment
alone. Clinical and demographic features demonstrated no
significant difference except for birth weight, which was
lower in Group I (Table 1). Twenty patients (35.7 %) were
diagnosed as culture-proven sepsis and others (nZ 36, 64.3
%) were diagnosed as suspected sepsis.
Thirteen (23.2 %) infants had radiographic evidence of
pneumonia, three (5.4 %) infants had necrotizing entero-
colitis, 13 (23.2 %) infants suffered from intraventricular
hemorrhage, seven (12.5 %) infants were diagnosed as
patent ductus arteriosus, 39 (69.6 %) infants had respiratory
distress syndrome, seven (12.5 %) infants had meningitis,
and six (10.7 %) infants developed bronchopulmonary
dysplasia (BPD). Follow-up period of patients ranged from 2
days to 7 days. Forty (71.4 %) infants survived to discharge.
Sixteen infants (28.6 %) died. No side effect that can be
attributed to rhG-CSF was observed.
Six patients, four in Group I and two in Group II, died
before their neutropenia subsided. Therefore, they were
excluded from the calculation of the day of recovery. All
were culture-proven sepsis. Duration of recovery was
significantly longer in Group II (3  1.5 days and 6  0.7
days, respectively; p < 0.001). ANC values were signifi-
cantly higher on the 2nd study day and 3rd study day in
Group I compared to Group II, whereas there was no dif-
ference in immature/mature cell ratios (Table 1).
In Group I, duration of recovery was significantly longer
in patients with culture-proven sepsis when compared with
patients with suspected sepsis (Table 2). Similarly, in Group
II duration of recovery was also longer in patients with
culture-proven sepsis (Table 2); however, this finding
lacked statistical significance.Table 1 Clinical and demographic features of the
patients.
Group I
(n Z 33)
Group II
(n Z 23)
p
Gestational
age (wk)
28.9  2 29.7  2 NS
Birth weight (g) 1001  240 1118  173 0.04
Gender
Female 10 (30) 6 (26) NS
Mode of delivery
Cesarean
delivery
29 (87.8) 19 (82.6) NS
SGA 8 (24.2) 4 (17.4) NS
PPROM 11 (33.3) 7 (30.4) NS
Culture-proven
sepsis
11 (34.3) 9 (39.2) NS
Outcome
Mortality 10 (30.3) 6 (26.1) NS
Data are presented as n (%) or mean  SD.
PPROM, preterm premature rupture of membranes; SGA, small
for gestational age.When patients with positive blood cultures were
analyzed separately it was documented that duration of
recovery was significantly shorter in infants who received
rhG-CSF when compared with infants in Group II
(p Z 0.005). Similarly, analyzing culture-negative patients
(suspected sepsis), we demonstrated that rhG-CSF admin-
istration shortened the duration of recovery also in these
infants (p Z 0.002; Table 3). That is, rhG-CSF shortened
duration of neutropenia both in infants with culture proven
sepsis and in those with suspected sepsis.
In Group I, 10 (30.3 %) infants died during hospitaliza-
tion. Seventy percent of these infants died after their
neutropenia had subsided and in 30% neutropenia did not
recover at all. Similarly, six infants (26.6%) in Group II died
of morbidities including stage IV necrotizing enterocolitis,
BPD, aspiration pneumonia and pneumothorax. Three of six
infants died after their neutropenia had subsided and, in
the remaining three, neutropenia did not recover at all.
Short-term mortality rate did not differ significantly be-
tween groups. Finally, none of the infants had altered liver
function tests (data not shown); and the number of
thrombocytopenic patients is given in Table 3.4. Discussion
In the present study, we demonstrated that treatment with
rhG-CSF results in a significantly more rapid recovery of the
ANC in neutropenic preterm infants with sepsis. However,
no reduction in short-term mortality was documented.
Theoretical concerns that rhG-CSF worsens respiratory
distress syndrome and BPD by overactivating systemic in-
flammatory response exist in the literature.23 Nonetheless,
treatment-related side effects (such as thrombocytopenia)
and toxic effects attributable to rhG-CSF were not detected
in our study population.
In accordance with previously published studies,24e26
our study documented that rhG-CSF induced a significant
increase in ANC in neonates with systemic infections.
Conversely, Schibler et al27 failed to demonstrate a signif-
icant increase in ANC after rhG-CSF infusion. Their study
was performed on 20 neonates with heterogeneous gesta-
tional ages and only six of the study participants had
culture-proven sepsis. These studies varied with respect to
design and patient population but no adverse events were
reported. Only one caseecontrol study investigating the
efficacy of rhG-CSF infusion to low birthweight infants with
neutropenia and sepsis has shown a reduction of short-term
mortality.28 However, our study failed to document a short-
term survival advantage in the study group who received
rhG-CSF compared to the control group.
In Cochrane Systematic Review, Carr and Modi22 pub-
lished a meta-analysis of seven studies to determine the
safety and efficacy of rhG-CSF to reduce mortality in the
treatment of suspected or proven systemic infections. They
concluded that there was no evidence to support the
addition of G-CSF or granulocyteemacrophage-CSF to
antibiotic therapy in preterm infants with suspected sys-
temic infection to reduce the immediate mortality. In
addition, no significant survival advantage was seen at 14
days from the start of therapy [typical risk ratio (RR) 0.71
(95% confidence interval, CI, 0.38, 1.33); typical risk
Table 3 Comparison of peripheral blood neutrophil counts, thrombocyte counts, and band/total leukocyte ratios between
groups.
Group I (n Z 33) Group II (n Z 23) p
Day of recovery of neutropenia (n Z 30/20) 2.6  0.7 4.3  1.5 < 0.001
Number of thrombocytopenic infants*
1st day (n Z 33/23) 17 (51.5) 10 (43.5) 0.38
2nd day (n Z 33/23) 18 (54.5) 13 (56.5) 0.55
3rd day (n Z 19/21) 10 (52.6) 12 (57.1) 0.51
ANC
1st day (n Z 33/23) 556  158.6 508  164.8 0.275
2nd day (n Z 33/23) 1034  583.7 702  535.2 < 0.001
3rd day (n Z 19/21) 1150  351.8 755  309.2 < 0.001
Immature/mature
1st day (n Z 33/23) 0.155  0.117 0.170  0.102 0.438
2nd day (n Z 33/23) 0.158  0.120 0.176  0.182 0.701
3rd day (n Z 19/21) 0.157  0.108 0.103  0.077 0.057
Data are presented as n (%) or mean  SD.
ANC, absolute neutrophil count; SD, standard deviation.
* Platelet count < 100  109/L was defined as thrombocytopenia.
Table 2 Comparison of duration of recovery of neutropenia in Groups I and II.
Group I (n Z 30) Group II (n Z 20) p
Duration of recovery of neutropenia of
infants with culture (þ) sepsis (d)
3.1  0.6 4.8  1.3 0.005
Duration of recovery of neutropenia of
infants with suspected sepsis (d)
2.4  0.6 3.7  1.5 0.002
p 0.01 0.09
Data are presented as mean  SD.
SD, standard deviation.
174 D. Aktas‚ et aldifference (RD) 0.05 (95% CI, 0.14, 0.04)]. However, all
seven studies had small sample size, the largest recruiting
only 60 infants. The subgroup analysis of 97 infants from
three treatment studies who, in addition to systemic
infection, had clinically significant neutropenia
(< 1.7  109/L) at trial entry, does show a significant
reduction in mortality by Day 14 [RR, 0.34 (95% CI, 0.12,
0.92); RD, 0.18 (95% CI, 0.33, 0.03); number needed to
treat, 6 (95% CI, 3, 33)]. However, our study could not
document a decrease in short-term mortality in patients
who received rhG-CSF, although they were even more
neutropenic (< 1  109 /L) at trial entry.
In some studies, rhG-CSF was administered for 5e10
days.21,24,26 However, in our study neutropenia recovered
on 2.2  1.4 days in Group I and rhG-CSF infusions were
halted as soon as ANC rose above 1  109 /L. Instead of
administering rhG-CSF for constant periods, it may be more
reasonable to perform daily CBC and terminate rhG-CSF
infusions as soon as ANC is over 1  109 /L. Therefore,
potential toxicity and adverse effects may be minimized.
Duration of recovery of neutropenia in infants with
positive blood cultures was longer compared with infants
who have negative blood cultures. This finding may be
attributed to a smaller neutrophil storage pool, a reduced
capacity for neutrophil mobilization from bone marrow
reserves, and a slower regeneration of neutrophils in the
preterm bone marrow.14The limitations of this study are that it is not placebo-
controlled and it has a relatively small sample size. The
long-term survival and neurodevelopmental outcomes are
important outcome measures that are lacking in this study.
These outcome measures should be investigated in ran-
domized placebo-controlled studies recruiting larger sam-
ples of neutropenic preterm infants with clinical sepsis in
order to settle the controversy surrounding routine use of
rhG-CSF for the treatment of neutropenia associated with
preterm systemic infections.Conflicts of interest
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